Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
24.82
-0.45 (-1.78%)
Aug 13, 2026, 4:00 PM EDT - Market closed
Denali Therapeutics Revenue
Denali Therapeutics had revenue of $3.60M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $3.60M.
Revenue (ttm)
$3.60M
Revenue Growth
n/a
P/S Ratio
1,100.84
Revenue / Employee
$7,108
Employees
507
Market Cap
3.97B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 330.53M | 222.07M | 204.74% |
| Dec 31, 2022 | 108.46M | 59.80M | 122.90% |
| Dec 31, 2021 | 48.66M | -287.00M | -85.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.27B |
| Telix Pharmaceuticals | 803.79M |
| IDEAYA Biosciences | 234.13M |
| Arcus Biosciences | 117.00M |
| Tango Therapeutics | 53.81M |
| Relay Therapeutics | 10.35M |
DNLI News
- 6 days ago - Denali Therapeutics price target raised to $40 from $36 at Morgan Stanley - TheFly
- 6 days ago - Denali Therapeutics price target raised to $34 from $25 at UBS - TheFly
- 6 days ago - Denali Therapeutics price target raised to $34 from $31 at Baird - TheFly
- 7 days ago - Denali Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 7 days ago - Denali Therapeutics Quarterly report: Q2 2026 - Filings
- 7 days ago - Denali Therapeutics Earnings release: Q2 2026 - Filings
- 7 days ago - Denali Therapeutics reports Q2 EPS (68c), consensus (47c) - TheFly
- 7 days ago - Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - GlobeNewsWire